RxDoctor Payments Data

Chad York, PA

Physician Assistant · Spartanburg, SCNPI 1891074241

Payments from drug & device makers

$5,848in general payments, 2019–2025

Across 308 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$730
  • Sun Pharmaceutical Industries Inc.$699
  • Lilly USA, LLC$507
  • Pfizer$502
  • Dermavant Sciences, Inc.$468
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,69197%
  • Education$1573%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,848 in reported general payments places this provider in the 90th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$177,001
Medicare patients
635
Services billed
3,961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab52$609,397
Skyrizi PenRisankizumab-Rzaa26$545,746
Cosentyx Sensoready (2 Pens)Secukinumab27$204,431
Dupixent PenDupilumab45$170,949
Cosentyx SyringeSecukinumab13$116,643
OtezlaApremilast12$67,882
AdbryTralokinumab-Ldrm13$49,907
VtamaTapinarof13$17,960
Clobetasol Propionate157$7,799
Calcipotriene19$3,535
Betamethasone Dipropionate83$3,430
Ketoconazole84$1,656
Triamcinolone Acetonide69$1,105
Fluorouracil18$1,035
Clindamycin Phosphate24$960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$98$67,88212 claims
LEO Pharma Inc.Adbry$238$49,90713 claims
Dermavant Sciences, Inc.Vtama$468$17,96013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →